Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients

Suzuki,Hideo; Roa,Juan  C.; Kawamoto,Toru; Ishige,Kazunori; Wistuba,Ignacio   I.; Li,Donghui; Thomas,Melanie  B.; Shoda,Junichi

doi:10.3892/mco.2015.515

Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients

Authors:
- Hideo Suzuki
- Juan C. Roa
- Toru Kawamoto
- Kazunori Ishige
- Ignacio I. Wistuba
- Donghui Li
- Melanie B. Thomas
- Junichi Shoda
View Affiliations

Affiliations: Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Molecular Pathology Laboratory, Department of Pathology, Pontifical Catholic University of Chile, Santiago 8320000, Chile, Minato Shiba Clinic, Tokyo 105‑0014, Japan, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC 29425, USA
Published online on: February 25, 2015 https://doi.org/10.3892/mco.2015.515
Pages: 464-470
Copyright: © Suzuki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carcinomas of the gallbladder (GBCa) and bile ducts are aggressive tumors with poor survival and it is, therefore, essential to elucidate the molecular mechanisms of the various signaling pathways in order to develop effective therapies. In this study, tumor specimens from 40 GBCa patients, 12 extrahepatic bile duct carcinoma patients and 26 intrahepatic bile duct carcinoma patients from the USA and Japan were investigated for insulin‑like growth factor I receptor (IGF‑IR), mammalian target of rapamycin (mTOR) and rapidly accelerated fibrosarcoma‑1 (Raf‑1) expression by immunohistochemistry; in addition, the correlations with histological type, pathological stage and patient outcome were analyzed. Positive expression of IGF‑IR, mTOR and Raf‑1 were identified in 68, 73 and 85% of the specimens, respectively. There was no association with histological type and pathological stage, although the positive expression rate of Raf‑1 was higher in advanced‑stage GBCa. Moreover, patients with positive expression of IGF‑IR exhibited significantly reduced survival compared to those with negative IGF‑IR expression. In conclusion, IGF‑IR, mTOR and Raf‑1 were highly expressed in biliary tract cancer and targeted therapy against IGF‑IR may be an effective strategy. Among these molecules, IGF‑IR expression was found to be a useful biomarker for identifying patients who may benefit from additional treatment.

View Figures

View References

1	Jarnagin WR, Ruo L, Little SA, et al: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 98:1689–1700. 2003. View Article : Google Scholar : PubMed/NCBI
2	Shaib YH, Davila JA, McGlynn K and El-Serag HB: Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 40:472–477. 2004. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Murray T, Ward E, et al: Cancer statistics 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
4	Randi G, Franceschi S and La Vecchia C: Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 118:1591–1602. 2006. View Article : Google Scholar : PubMed/NCBI
5	Roa I, Araya JC, Villaseca M, Roa J, de Aretxabala X and Ibacache G: Gallbladder cancer in a high risk area: morphological features and spread patterns. Hepatogastroenterology. 46:1540–1546. 1999.PubMed/NCBI
6	Medina E and Kaempffer AM: Cancer mortality in Chile: epidemiological considerations. Rev Med Chil. 129:1195–1202. 2001.[(In Spanish)]. View Article : Google Scholar : PubMed/NCBI
7	Kimura K, Ohto M, Saisho H, et al: Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology. 89:1258–1265. 1985.PubMed/NCBI
8	Kawamoto T, Krishnamurthy S, Tarco E, et al: HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest Cancer Res. 1:221–227. 2007.PubMed/NCBI
9	Watanabe H, Date K, Itoi T, et al: Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann Oncol. 10 (Suppl 4):136–139. 1999. View Article : Google Scholar : PubMed/NCBI
10	Furstenberger G and Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol. 3:298–302. 2002. View Article : Google Scholar : PubMed/NCBI
11	Papa V, Gliozzo B, Clark GM, et al: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 53:3736–3740. 1993.PubMed/NCBI
12	Matsubara J, Yamada Y, Hirashima Y, et al: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res. 14:3022–3029. 2008. View Article : Google Scholar : PubMed/NCBI
13	LeRoith D and Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett. 195:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
14	Mauro L and Surmacz E: IGF-I receptor, cell-cell adhesion, tumor development and progression. J Mol Histol. 35:247–253. 2004. View Article : Google Scholar : PubMed/NCBI
15	Reinmuth N, Fan F, Liu W, et al: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 82:1377–1389. 2002. View Article : Google Scholar : PubMed/NCBI
16	Imsumran A, Adachi Y, Yamamoto H, et al: Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 28:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kornprat P, Rehak P, Ruschoff J and Langner C: Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumors. J Clin Pathol. 59:202–206. 2006. View Article : Google Scholar : PubMed/NCBI
18	Ohashi H, Adachi Y, Yamamoto H, et al: Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers. Cancer Sci. 103:252–261. 2012. View Article : Google Scholar : PubMed/NCBI
19	Karp DD, Paz-Ares LG, Novello S, et al: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 27:2516–2522. 2009. View Article : Google Scholar : PubMed/NCBI
20	Asnaghi L, Bruno P, Priulla M and Nicolin A: mTOR: a protein kinase switching between life and death. Pharmacol Res. 50:545–549. 2004. View Article : Google Scholar : PubMed/NCBI
21	Richardson CJ, Schalm SS and Blenis J: PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol. 15:147–159. 2004. View Article : Google Scholar : PubMed/NCBI
22	Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell. 124:471–484. 2006. View Article : Google Scholar : PubMed/NCBI
23	Ito Y, Takeda T, Sasaki Y, et al: Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract. 197:95–100. 2001. View Article : Google Scholar : PubMed/NCBI
24	Yukawa M, Fujimori T, Hirayama D, et al: Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. Hum Pathol. 24:37–40. 1993. View Article : Google Scholar : PubMed/NCBI
25	Suzuki H, Isaji S, Pairojkul C and Uttaravichien T: Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan. J Hepatobiliary Pancreat Surg. 7:206–211. 2000. View Article : Google Scholar : PubMed/NCBI
26	Ukita Y, Kato M and Terada T: Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol. 36:780–785. 2002. View Article : Google Scholar : PubMed/NCBI
27	Leal P, Garcia P, Sandoval A, et al: Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. Arch Pathol Lab Med. 137:552–557. 2013. View Article : Google Scholar : PubMed/NCBI
28	Leal P, Garcia P, Sandoval A, et al: AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther. 6:1373–1384. 2013.PubMed/NCBI
29	Wu Q, Kiguchi K, Kawamoto T, et al: Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 67:3794–3800. 2007. View Article : Google Scholar : PubMed/NCBI
30	Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 351:289–305. 2000. View Article : Google Scholar : PubMed/NCBI
31	Cleveland JL, Troppmair J, Packham G, et al: v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene. 9:2217–2226. 1994.PubMed/NCBI
32	Erhardt P, Schremser EJ and Cooper GM: B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol. 19:5308–5315. 1999.PubMed/NCBI
33	McPhillips F, Mullen P, Monia BP, et al: Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer. 85:1753–1758. 2001. View Article : Google Scholar : PubMed/NCBI
34	Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J and Brambilla C: Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur J Cancer B Oral Oncol. 31B:384–391. 1995. View Article : Google Scholar : PubMed/NCBI